key: cord-0890996-1pxyrjw0
authors: Scorsetti, Marta; Goodman, Karyn A.; Seong, Jinsil; Loi, Mauro; Huguet, Florence; Dawson, Laura A.
title: Hepatocellular Carcinoma (HCC) in the COVID‐19 era: Primetime for Stereotactic Body Radiotherapy and a lesson for the future?
date: 2020-06-11
journal: Oncologist
DOI: 10.1634/theoncologist.2020-0416
sha: 6cb2db7d237a8ad24556c7144968d29d5da783da
doc_id: 890996
cord_uid: 1pxyrjw0

nan

As the COVID-19 pandemic spreads across the globe, major transformations are rapidly being implemented due to the unprecedented pressure on healthcare systems. Management of cancer patients has been particularly impacted by the reduced access to cancer treatments related to prolonged wait times for diagnostic and interventional procedures, treatment delays or interruptions, fragmentation of multidisciplinary management with a shrinking oncology workforce, and self-isolation for fear of nosocomial infection. Consequently, there is a risk of detrimental consequences for this highly vulnerable patient population. This dire scenario represents an opportunity to evaluate current practices, and provide a lesson for the future in the post-COVID-19 era. The case of Stereotactic Body Radiotherapy (SBRT) in Hepato-Cellular Carcinoma (HCC) is emblematic.

SBRT has emerged as a non-invasive, painless and effective therapeutic modality delivered in few daily fractions over less than one week for HCC patients, from early to advanced stage.

In early stage HCC, local therapy can be offered as a definitive or bridging treatment [1]. Due to current restrictions in access to operating rooms and the redeployment of anesthesiologists to intensive care units, SBRT represents an appealing option compared to invasive local therapies such as surgery, radiofrequency/microwave ablation and regional therapies such as trans-arterial or radio-embolization, which may require general anesthesia and recovery. While randomized trials are lacking, indirect comparisons suggest comparable efficacy of SBRT with these treatment modalities for similar stage patients [2, 3, 4] . The use of SBRT may reduce the need for systemic therapy in advanced patients with symptomatic involvement or poor responders to standard treatment, e.g. macroscopic vascular invasion [5] .

Despite the numerous studies demonstrating efficacy, long term survival and low toxicity rates [6] [7] [8] , many current HCC treatment algorithms do not incorporate SBRT in the management of HCC. Most limit its use to patients who are ineligible for or refractory to other invasive local and/or regional therapies. The significant time and effort required, coupled with the limited funding and lack of pharmaceutical and vendor support, have been an impediment to conducting large-scale, potentially practice-changing clinical trials of SBRT for HCC: thus, SBRT may be indefinitely relegated to an ancillary role.

It is expected that, during the COVID-19 pandemic and its aftermath, SBRT will increasingly represent a preferred treatment that may relieve the burden of interrupted and deferred cancer treatments, the overload of chemotherapy facilities and patient exposure and risk of COVID infection due to repeated visits and prolonged stays in the hospital [8] . With more widespread clinical use of SBRT, there may be an increase in support for trials of this effective HCC treatment. It is crucial that outcome and toxicity data be recorded during this time, when non-standard therapies are offered. This data will hopefully provide further evidences to reconsider SBRT as a first-line treatment option for HCC (proposed algorithm in Figure 1 ).

It is our hope that the cumulative global experience gained during the COVID-19 pandemic may allow for a full recognition of SBRT as a useful therapy in the management of HCC based on real-life evidence. 

Multicenter Phase 2 Trial

Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review

Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma

Stereotactic Body Radiation Therapy as an Alternative to Transarterial Chemoembolization for Hepatocellular Carcinoma

Stereotactic body radiotherapy based treatment for hepatocellular carcinoma with extensive portal vein tumor thrombosis

High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma

Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation

Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma

Recommendations on the use of radiation therapy in managing patients withgastrointestinal malignancies in the era of COVID-19